

express mail ED 635477137 US

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the American Information Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/750,475
Filing Date	12-31-2003
First Named Inventor	Alavattam et al.
Art Unit	1653
Examiner Name	Gargi Roy <i>UG</i>
Attorney Docket Number	13447

Sheet 1 of 6**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
<i>MR</i>	A1	US- 3,773,919	11-20-1973	Boswell et al.	
<i>MR</i>	A2	US- 3,887,699	06-03-1975	Yolles	
<i>MR</i>	A3	US- 4,293,339	10-06-1981	Supcoe et al.	
<i>MR</i>	A4	US- 4,675,189	06-23-1987	Kent et al.	
<i>MR</i>	A5	US- 5,700,486	12-23-1997	Canal et al.	
<i>MR</i>	A6	US- 5,759,583	06-02-1998	Iwamoto et al.	
<i>MR</i>	A7	US- 5,981,719	11-09-1999	Woiszwillo et al.	
<i>MR</i>	A8	US- 5,985,309	11-16-1999	Edwards et al.	
<i>MR</i>	A9	US- 6,120,787	09-19-2000	Gustafsson et al.	
<i>MR</i>	A10	US- 6,238,705	05-29-2001	Liu et al.	
<i>MR</i>	A11	US- 6,294,202	09-25-2001	Burns et al.	
<i>MR</i>	A12	US- 6,391,296	05-21-2002	Okano et al.	
<i>MR</i>	A13	US- 6,896,894	05-24-2005	Brody et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
<i>MR</i>	A14	EP 0 950 663 A1	10-20-1999	Okano et al.		
<i>MR</i>	A15	WO 02/28370 A1	04-11-2002	Jonsson et al.		

Examiner
SignatureDate
Considered*2/15/06*

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/750,475
Filing Date	12-31-2003
First Named Inventor	Alavattam et al.
Art Unit	1653
Examiner Name	Gargi, Roy <i>LR</i>
Attorney Docket Number	13447

Sheet 2

of

6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>MR</i>	B1	AUSTIN et al.; The Controlled Release of Leukaemia Inhibitory Factor (LIF) From Aliginate Gels; Pro Intern Symp Control Rel Bioact Mater; 23; 1996; pp 739-740	
<i>MR</i>	B2	BRANNON-PEPPEAS et al.; Polyactic and Polyglycolic Acids as Drug Delivery Carriers; Handbook of Pharmaceutical Release Tech; 2000; pp 99-130; Marcel Dekker; New York	
<i>MR</i>	B3	BURGESS et al.; Glucuronidase Activity Following Complex Coacervation & Spray Drying Micoencapsulation; J. Microencapsulation; 1998; Vol 15; No. 5; pp. 569-579	
<i>MR</i>	B4	BURKE, PAUL; Controlled Release Protein Therapeutics: Effects of Process & Formulation on Stability; Handbook of Pharmaceutical Controlled Release Tech; 2000; pp. 661-692;	
<i>MR</i>	B5	CHANG, THOMAS; Biodegradable Semipermeable Microcapsules Containing Enzymes Hormones Vaccines & Other Biologicals; J of Bioengineering; 1976; Vol 1; pp 25-32	
<i>MR</i>	B6	CHEN et al. Polysaccharide Hydrogels for Protein Drug Delivery; Carbohydrate Polymers 28; 1995; pp 69-76; Elsevier; Great Britain	
<i>MR</i>	B7	CLELAND et al.; Stable Formulations of Recombinant Human Growth Hormone & Interferon-for Microencapsulation in Biodegradable Microspheres; Pharmaceutical Research; Vol 13; No 10; 1996; pp. 1464-1475	
<i>MR</i>	B8	CROTTS et al. Protein Delivery From Poly(lactic-co-glycolic acid) Biodegradable Microspheres: Release Kinetics & Stability Issues; J Microencapsulation 1998; 15; 6; pp 699-713	
<i>MR</i>	B9	DE ROSA et al; Influence of Co-encapsulation of Different Non-ionic Surfactants on the Properties of PLGA Insulin-loaded Microspheres; J Controlled Release 69 2000 pp 283-295	

Examiner Signature	<i>[Signature]</i>	Date Considered	2/15/04
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/750,475
Filing Date	12-31-2003
First Named Inventor	Alavattam et al.
Art Unit	1653
Examiner Name	Gargi, Roy WAX
Attorney Docket Number	13447


Sheet 3

of

6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MW	C1	GOMBOTZ et al.; Protein Release From Alginate Matrices; Advanced Drug Delivery Reviews; 31; 1998; pp 267-285; Elsevier	
MW	C2	HUANG et al.; On The Importance & Mechanisms of Burst Release in Matrix-controlled Drug Delivery Systems; J of Controlled Release; 73; 2001; pp 121-136; Elsevier	
MW	C3	JAIN et al.; Controlled Drug Delivery by Biodegradable Poly(Ester) Devices: Different Preparative Approaches; Drug Development & Industrial Pharmacy; 1998; Vol 24; pp 703-727	
MW	C4	JIANG et al.; Stabilization & Controlled Release of Bovine Serum Albumin Encapsulated in Poly(D, L-lactide) and Poly(ethylene glycol) Microsphere Blends; Pharmaceutical Research; Vol 18; 6; 2001; pp 878-885	
MW	C5	JOHANSEN et al; Improving Stability & Release Kinetics of Microencapsulated Tetanus Toxoid by Co-Encapsulation of Additives; Pharmaceutical Research Vol 15; 7 1998 pp 1103-1110	
MW	C6	LEE et al.; Double Walled Microparticles For HBV Single Shot Vaccine; Proceed Intern Symp Control Rel Bioact Mater; 23; 1996; pp 333-334; #4103; Controlled Release Soc	
MW	C7	LI et al.; A Novel Biodegradable System Based on Gelatin Nanoparticles and Poly(lactic-co-glycolic acid) Microspheres for Protein and Peptide Drug Delivery; J Pharmaceutical Sciences; Vol 86; No 8; August, 1997; pp 891-895	

Examiner Signature		Date Considered	2/15/06
--------------------	---	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citations in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/750,475
		Filing Date	12-31-2003
		First Named Inventor	Alavattam et al.
		Art Unit	1653
		Examiner Name	Gargi, Roy, Waxy
Sheet 4	of 6	Attorney Docket Number	13447

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>AW</i>	D1	MORLOCK et al., Erythropoietin Loaded Microspheres Prepared From Biodegradable-LPLG-POE-LPLG Triblock Copolymers: Protein Stabilization and In-vitro Release Properties;	
		J of Controlled Release; 56; 1998; pp 105-115; Elsevier	
<i>MW</i>	D2	PARK et al.; Poly(L-lactic acid) Pluronic Blends: Characterization of Phase Separation Behavior, Degradation and Morphology and Use as Protein-Releasing Matrices;	
		Macromolecules; 1992; 25; pp 116-122; American Chemical Society	
<i>MW</i>	D3	PATIL et al.; Water-Based Microsphere Delivery System for Proteins; J of Pharmaceutical Sciences; Vol 89; No 1; January 2000; pp 9-15	
<i>MW</i>	D4	PEAN et al.; Why Does PEG 400 Co-Encapsulation Improve NGF Stability & Release From PLGA Biodegradable Microspheres; Pharmaceutical Research; Vol 16; No 8; 1999; pp 1294-1299	
<i>MW</i>	D5	PROKOP et al.; Water Soluble Polymers ^{for} Immunoisolation II: Evaluation of Multicomponent Microencapsulation Systems; Advances in Polymer Science; Vol 136; pp 53-73; 1998	
<i>MW</i>	D6	PUTNEY et al.; Encapsulation of Proteins for Improved ^{et} Delivery; Current Opinion In Chemical Biology; 1998; 2 pp 548-552	
<i>MW</i>	D7	ROSKOS et al.; Degradable Controlled Release Systems Useful for Protein Delivery; Protein Delivery: Physical Systems, Sanders & Hendren eds.; Plenum Press; NY; pp 45-92; 1997	

Examiner Signature	<i>Pat M...</i>	Date Considered	2/15/06
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/750,475
Filing Date	12-31-2003
First Named Inventor	Alavattam et al.
Art Unit	1653
Examiner Name	Gargi, Roy Wgx
Attorney Docket Number	13447

Sheet 5

of

6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MPW	E1	SANCHEZ et al.; Formulation Strategies for Stabilization of Tetanus Toxoid in Poly (lactide-co-glycolide) Microspheres; Inter J of Pharmaceutics; 185; 1999 pp 255-266; Elsevier	
MPW	E2	SANDOR et al.; Effect of Protein Molecular Weight on Release From Micro-Sized PLGA Microspheres; J of Controlled Release; 76; 2001; pp 297-311; Elsevier	
MPW	E3	SEZER et al.; Release Characteristics of Chitosan Treated Alginate Beads: I. Sustained Release of a Macromolecular Drug From Chitosan Treated Alginate Beads; J Microencapsulation; 1999; Vol 16; No 2; pp 195-203	
MPW	E4	Van DE WEERT et al.; Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles; Pharmaceutical Research; Vol 17; No 10; 2000; pp 1159-1167	
MPW	E5	WAKEMAN et al.; Concentration and Fractionation of Polyvinyl Alcohol anionic Surfactant Stabilised Latex Dispersions by Microfiltration; J Membrane Science; 106; 1995 pp 57-65	
MPW	E6	WANG et al.; A heterogenously Structured Composite Based on Poly(lactic-co-glycolic acid) Microspheres and Poly (vinyl alcohol) Hydrogel Nanoparticles for Long-Term Protein Drug Delivery; Pharmaceutical Research; Vol 16; No 9; 1999; pp 1430-1435	
MPW	E7	WANG et al.; A Novel Approach to Stabilization of Protein Drugs in Poly(lactic-co-glycolic acid) microspheres Using Agarose Hydrogel; International Journal of Pharmaceutics; 166; 1998; pp 1-14	

Examiner Signature		Date Considered	2/15/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/750,475
		Filing Date	12-31-2003
		First Named Inventor	Alavattam et al.
		Art Unit	1653
		Examiner Name	Gargi Roy Wax
Sheet 6	of 6	Attorney Docket Number 13447	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MR	F1	WHEATLEY et al.; Coated Alginate Microspheres: Factors Influencing the Controlled Delivery of Macromolecules; J of Applied Polymer Science; Vol 43; pp 2123-2135; 1991	
MW	F2	WOO et al.; Preparation and Characterization of a Composite PLGA and Poly(Acryloyl Hydroxyethyl Starch) Microsphere System for Protein Delivery; Pharmaceutical Research; Vol 18; No. 11; November, 1992; pp 1600-1606	
SA	F3	ZHU et al.; Stabilization of Proteins Encapsulated in Injectable Poly(lactide-co-glycolide); Nature Biotechnology; Vol 18; January, 2000; pp 52-57	

Examiner Signature		Date Considered	2/15/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.